Why a Fund Manager Bet on Elevance Health After Years of Staying Away

A Position Closed, Then Reopened

For a while, Baron Health Care Fund didn’t own Elevance Health at all. That is not a small detail. A fund that specializes in health care, run by people whose job is to watch this sector daily, walked away from one of the country’s largest health benefits companies and stayed away for years. Then, in the second quarter of 2026, it walked back in.

That reversal is the real story here, more than the Elevance Health margin figures that triggered it. Money managers rarely announce a mistake by quietly re-buying what they sold. When they do, something about the underlying business has genuinely changed, not just the stock price.

What Showed Up in the Numbers

The occasion for this renewed attention was Baron Capital’s Q2 2026 investor letter for its Health Care Fund, one of many such letters investment managers publish each quarter to explain their trades to shareholders. Baron’s fund had a strong quarter — up 11.99%, ahead of the Russell 3000 Health Care Index’s 10.48% gain, though behind the broader Russell 3000 Index’s 15.44% climb. Since its inception, the fund has compounded at 10.61% annually, edging out its health care benchmark’s 10.02% but trailing the wider market’s 14.83%.

Buried inside that letter was a specific decision: the fund re-established positions in both UnitedHealth Group and Elevance Health, two companies it had previously exited. On August 3, 2026, Elevance Health shares closed at $382.77, putting the company’s market value near $81.54 billion. The stock had fallen 8.61% over the prior month alone, yet was still up 38.48% over the trailing 52 weeks — a swing that tells its own story about how uneven the market’s confidence in managed care has been.

The Business Nobody Wants to Explain at a Dinner Party

Elevance Health, formerly known as Anthem, sells health insurance. It manages benefits for people covered through employers, government exchanges, Medicaid, and — the segment that matters most to this story — Medicare Advantage, the privately administered alternative to traditional Medicare that now covers more than half of eligible seniors nationwide.

The insurance model looks simple from the outside: collect premiums, pay claims, keep the difference. In practice, the margin between those two numbers is one of the most fought-over figures in corporate America, shaped by government reimbursement rates, member health patterns, competitive pricing, and years-long strategic bets that can look brilliant or disastrous depending on how a handful of assumptions play out.

Why This Surfaced Now

Elevance Health has been part of the financial news cycle recently as investors digest quarterly filings and repositioning by major funds. That attention is a symptom, not the cause — it reflects a broader recalibration happening across the managed care sector as companies report on how their Medicare Advantage businesses are performing after several difficult years.

The Years That Broke the Model

To understand why Baron’s fund left in the first place, you have to understand what happened to Medicare Advantage margins starting several years earlier. Insurers had spent years competing aggressively for enrollment, offering richer benefits — dental coverage, gym memberships, transportation, reduced cost-sharing — to win members away from rivals and from traditional Medicare. That strategy worked on the growth side. Enrollment climbed.

But two forces collided against it. First, utilization trends rose: members used more medical services than insurers had priced for, particularly as deferred care from the pandemic years worked its way back into the system. Second, government reimbursement — the rate at which Medicare pays insurers per enrolled member — did not keep pace with those rising costs, squeezed further by regulatory changes to how risk scores and quality bonuses are calculated.

The result was a pincer: revenue per member grew more slowly than the cost of caring for that member. Layer in benefits that had been priced too generously to win market share, and operating margins in Medicare Advantage fell to levels that made the business barely profitable in some markets, and outright unprofitable in others.

What Elevance Did About It

Elevance’s response, according to Baron’s letter, was not cosmetic. The company exited Medicare Advantage markets and specific plan products where it could not price its way back to profitability. It scaled back some of the richer benefits that had been used to chase enrollment. This is the unglamorous, unpopular part of running an insurer: choosing to shrink deliberately in places where growth had stopped making financial sense.

This is also where the mechanism behind managed care margins becomes visible. Health insurers don’t set their prices the way most businesses do. Medicare Advantage premiums and reimbursement rates are negotiated within a federal framework, and profitability depends heavily on accurately forecasting how sick a given pool of members will be in the coming year — a discipline called risk adjustment. Get that forecast wrong, price benefits too rich, or absorb a sicker-than-expected membership base, and the margin compresses even if enrollment numbers look healthy on a slide deck. Elevance’s retreat from unprofitable markets was, in effect, an admission that its earlier pricing had been wrong for the risk it was carrying — and a correction aimed at getting the equation right again.

The AI Argument Baron Is Making

Baron’s letter adds a second leg to its thesis beyond simple market discipline: artificial intelligence applied to administrative costs. Health insurers carry enormous back-office overhead — claims processing, prior authorization review, provider network management, fraud detection, customer service. These functions are labor-intensive, rules-heavy, and historically resistant to automation because the judgment calls involved are complex.

The fund’s bet is that AI tools can now take a meaningful bite out of that overhead, not by replacing clinical judgment but by accelerating the administrative machinery around it — flagging claims, routing authorizations, catching errors faster than manual review allows. If that materializes at scale across an insurer as large as Elevance, the savings show up directly in operating margin, because administrative cost is one of the few big line items an insurer can actually control, unlike medical costs, which are driven largely by member health and provider pricing.

A Bet on Discipline, Not Discovery

Here is the part worth sitting with: Baron isn’t betting that Elevance found a new source of revenue. It’s betting on a return to discipline after a period of self-inflicted damage. The company spent years chasing market share with pricing that didn’t match its risk, then spent more time unwinding that mistake. Baron’s re-entry is a wager that the correction is mostly finished and that the next stretch is about the company simply behaving the way a well-run insurer should — pricing risk accurately, keeping benefits sustainable, running overhead efficiently.

That is a very different kind of investment thesis than betting on growth or innovation. It’s a bet on the absence of self-sabotage. Baron’s letter is explicit that it believes Elevance’s earnings power is

Where Baron’s Optimism Could Break

None of this is guaranteed. Baron’s letter frames its optimism around Elevance and UnitedHealth

What This Means Beyond One Stock

The Elevance Health margin story is really a case study in how a specific kind of business — one that prices a promise years before it has to deliver on it — recovers from a pricing mistake. That pattern isn’t unique to health insurance. Any business where the price is locked in long before the true cost is known (long-term contracts, subscription services, warranty-heavy products) faces a version of the same risk: the temptation to price aggressively for growth today, and the reckoning that follows if the cost side runs hotter than expected.

For everyday readers, the practical takeaway is narrower but still useful: Medicare Advantage’s benefit generosity — the extras that made it attractive relative to traditional Medicare — has been trimmed industrywide as insurers repair margins. Anyone comparing Medicare Advantage plans during open enrollment is likely to notice that some of the perks available a few years ago have quietly become less common, a direct downstream effect of the same margin pressure Baron’s letter describes.

Where the Fund’s Confidence Rests

Baron’s letter notes that Elevance was not among the 40 most popular stocks held by hedge funds tracked in the relevant database, even though the number of hedge fund portfolios holding the stock rose from 78 to 87 between quarters — a modest but real increase in institutional interest. That is a company being rediscovered gradually, not one riding a wave of consensus enthusiasm. For a fund manager, that gap between quiet accumulation and broad popularity is often exactly the moment worth watching, because it means the thesis hasn’t yet been fully priced in by everyone else.

FAQ

Why did Elevance Health’s margins fall in the first place?

Years of aggressive benefit pricing aimed at winning Medicare Advantage enrollment collided with rising medical utilization and reimbursement rates that didn’t keep pace, compressing operating margins across the business.

What is Elevance Health doing to rebuild profitability?

According to Baron Capital’s investor letter, Elevance has exited unprofitable Medicare Advantage markets and products, scaled back overly generous benefits, and is applying AI tools to reduce administrative overhead.

Is Elevance Health the same company as Anthem?

Yes. Elevance Health was formerly named Anthem and rebranded, though its core business remains managing health insurance benefits across commercial, exchange, Medicaid, and Medicare Advantage markets.

Does a rising stock price mean Elevance Health’s margin problems are fully solved?

Not necessarily. The stock’s 52-week gain reflects investor expectations about future improvement, but the letter frames its optimism as a forecast tied to the company reaching long-term target margins, not a confirmed outcome.

How does AI help an insurance company’s margins?

Insurers carry heavy administrative costs from claims processing, authorization review, and network management. AI tools can speed up these rules-based tasks, and because administrative cost is one of the few expenses insurers can directly control, efficiency gains there flow straight into operating margin.

Related Reading

• The 25-Year-Old Whose Fund Went From 439% to Wiped Out in One Month
• Why Next Year’s Social Security Raise Comes With a Warning Label

Official Source Links

For further reading and verification:

• https://finance.yahoo.com/healthcare/articles/elevance-health-elv-positioned-margin-152550451.html